Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Inhibrx Biosciences, Inc. (INBX : NSDQ)

• Company Description    Inhibrx Inc. is a clinical-stage biopharmaceutical company. It focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO. Number of Employees: 161

• Price / Volume Information    Yesterday's Closing Price: $16.33 Daily Weekly Monthly 20 Day Moving Average: 81,386 shares Shares Outstanding: 14.48 (millions) Market Capitalization: $236.39 (millions) Beta: -0.04 52 Week High: $17.79 52 Week Low: $10.80 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 26.69% 19.83% 12 Week 44.26% 21.02% Year To Date 6.04% -0.68%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11025 N. TORREY PINES ROAD SUITE 140 - LA JOLLA,CA 92037 USA ph: 858-795-4220 fax: - ir@inhibrx.com https://inhibrx.com

• General Corporate Information    Officers Mark P. Lappe - Chief Executive Officer and Chairman Kelly D. Deck - Chief Financial Officer Jon Faiz Kayyem - Director Douglas G. Forsyth - Director Kimberly Manhard - Director Peer Information Inhibrx Biosciences, Inc. (CORR.) Inhibrx Biosciences, Inc. (RSPI) Inhibrx Biosciences, Inc. (CGXP) Inhibrx Biosciences, Inc. (BGEN) Inhibrx Biosciences, Inc. (GTBP) Inhibrx Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45720N103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/12/25 Share - Related Items Shares Outstanding: 14.48 Most Recent Split Date: (:1) Beta: -0.04 Market Capitalization: $236.39 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-2.94 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-11.67 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 0.14 PEG Ratio: - Price Ratios Price/Book: 2.50 Price/Cash Flow: 0.14 Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 9.39% Sales Growth vs. Year Ago Period: -93.94% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -85.12 12/31/24 - -129.52 ROA 06/30/25 - - 03/31/25 - -58.90 12/31/24 - -97.73 Current Ratio 06/30/25 - - 03/31/25 - 5.12 12/31/24 - 3.94 Quick Ratio 06/30/25 - - 03/31/25 - 5.12 12/31/24 - 3.94 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - 861,486.44 12/31/24 - 843,787.00 Book Value 06/30/25 - - 03/31/25 - 6.52 12/31/24 - 9.23 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 1.04 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 51.09 12/31/24 - 0.00

Powered by Zacks Investment Research ©